EUVIMEDEUVIMED entdecken
Crossref

The Genotype—Phenotype Conundrum for Antimicrobial Susceptibility Testing

Austin Ing, Romney Humphries iD

Clinical Chemistry · 2023

DOI: 10.1093/clinchem/hvac159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von Austin Ing und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Vanderbilt University Medical Center, Nashville, USA. Hauptthemen laut MEDLINE: Anti-Infective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: bioMerieux, Qiagen, Momentum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bloodstream infections (BSI) are serious, life-threatening illnesses. Prompt initiation of effective antimicrobial therapy improves outcomes and reduces mortality rate. This task is complicated by the inexorable spread of antimicrobial resistance (AMR), necessitating increasingly broad empirical coverage to ensure efficacy against most pathogens causing BSI. Over the past decade, molecular rapid diagnostic tests (mRDTs) that yield an identification and assessment of the presence of acquired AMR genes within hours of a blood culture flagging positive have been become standard-of-care. While the correlation between AMR gene detection and antimicrobial susceptibility is imperfect, for some high-risk pathogens, knowledge of the absence or presence of a single AMR gene is sufficient to make substantive antimicrobial adjustments (1). Detection of gram-positive AMR genes targeted by US Food and Drug Administration (FDA)-cleared rapid diagnostic tests (i.e., the staphylococcal oxacillin resistance genes mecA and mecC, or enterococcal vancomycin resistance genes vanA and vanB) are tightly correlated with both susceptibility (AMR gene not detected) and resistance (AMR gene detected) to these antimicrobials. Gram positive infections, particularly staphylococci, are among the most common cause of BSI in the US and roughly 30% to 50% of Staphylococcus aureus harbor a mecA gene, making treatment decisions based on mRDTs that target mecA frequent and impactful. However, the presence or absence of AMR genes for gram-negative bacteria is less predictive of an organism’s susceptibility profile due to the complex and multi-factorial nature of gram-negative AMR. AMR in gram-negative bacteria includes not only acquired AMR genes but also mutational changes to antibiotic targets or changes to expression of porins or efflux pumps. Furthermore, the number of AMR genes that can result in resistance to a given antimicrobial class is vast—as an example, more than 2600 extended spectrum beta-lactamase genes have been described to date among gram-negative bacteria. Thus, mRDTs for gram-negative bacteria are limited to detection of only a subset of AMR mechanisms that may possibly present in patients with BSI. BSI RDTs currently FDA-cleared are limited to detection of the extended spectrum beta-lactamase, blaCTX-M, or the carbapenemase genes blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP, for gram-negative bacteria. The risk of an unexpressed or weak expression of a detected AMR gene by gram-negative bacteria resulting in unnecessary escalation of therapy is relatively low, but the risk of antibiotic resistance in the absence of AMR genes may be substantial and depends on local epidemiology (2). Most institutions in the US only rarely encounter carbapenem-resistant Enterobacterales (CRE) in blood cultures, and nearly 25% of CRE do not harbor any carbapenemase gene targeted by FDA-cleared mRDTs, such as blaKPC (2). As such, the relative impact to patient outcomes of using a rapid diagnostic test for detection of blaKPC in gram-negative BSI is largely unproven. However, these infections are important to recognize early: carbapenemase gene detection is a surrogate for resistance to not only the carbapenems, but most other antibiotics, as these genes are typically found along with AMR genes for nearly every antimicrobial class (2). In addition, infections cause by gram-negative bacteria that harbor blaKPC are associated with mortality rates of up to 50%, even when treated with the best available therapy (3). Finally, these organisms pose significant infection control risk and have led to many instances of hospital-based outbreaks. A large driver of poor outcomes and institutional spread is diagnostic delay. Recognition of a CRE infection and escalation to active therapy routinely takes 48 to 72 h (3). CRE are rarely covered for empirically in the US due to their infrequent occurrence and the cost associated with newer antimicrobials with activity against CRE, like ceftazidime–avibactam, over generic drugs, making diagnostic testing and knowledge of local epidemiology critical for patient management. The potential of mRDTs to substantially improve patient outcomes in those rare instances of these infections through more rapid escalation to active therapy is substantial. Satlin and colleagues (4) recently demonstrated in a retrospective multi-center study of patients whose blood cultures underwent blaKPC mRDT had both shorter times to receipt of active therapy (median, 24 h vs 50 h for patients without rapid diagnostic test, P = 0.007) and decreased 14-day (16% vs 37%, P = 0.007) and 30-day (24% vs 47%, P = 0.007) mortality. Clearly, rapid testing for these patients provides significant benefit. A much more common scenario however, is the report of “no KPC gene detected” for gram-negative bacteria, leading clinicians to decide on the opportunity to de-escalate therapy to a more narrow-spectrum antimicrobial. De-escalation is associated with significant clinical value as it translates into diminished risk for the patient of acquiring or developing AMR infections, acquiring Clostridioides difficile infection, or experiencing other adverse drug events. The risk for each increases with each day of inappropriately broad antimicrobials. That being said, because of the multifaceted nature of AMR in gram-negative bacteria, the absence of one or more AMR genes alone does not result in many opportunities for de-escalation. Banerjee et al. (1) in fact showed no impact on time to antibiotic de-escalation when a mRDT for the KPC gene was used for patients with gram-negative BSI in a randomized controlled trial, underscoring the challenges with diagnostic uncertainty for AMR infections. These studies (1, 5) clearly demonstrate accurate and timely microbiologic data is a clinician’s most reliable tool in combating AMR while optimizing patient outcomes. However, it must be emphasized that interpretation and action with this tool requires intervention by antimicrobial stewardship programs (ASPs). Across the US, ASPs are required by the Centers for Medicare and Medicaid Services for all hospitals, as a condition of participation. These programs ensure adherence to national guidelines for the optimization of antibiotic use through stewardship, and to reduce development and transmission of healthcare-associated infections. Importantly, these programs also improve the care and safety of patients with infections—one of the highest yield activities of ASPs is active intervention on the results of mRDT results generated by the clinical microbiology laboratory. This concept was well illustrated by Banerjee et al., who conducted a prospective trial of patients with positive blood cultures randomized to standard-of-care culture and antimicrobial susceptibility testing, rapid diagnostic tests detection of AMR genes with templated comments, or rapid diagnostic tests with templated comments paired with real-time audit and feedback by an ASP. In this study, both groups undergoing rapid AMR gene detection had decreased broad-spectrum antimicrobial use and less contaminant treatment. ASP team involvement led to improved antibiotic de-escalation, appropriate antibiotic escalation, optimization of antibiotic dose or duration, and infectious diseases physician consultation. As noted by the authors, this could be in part due to direct notification from the intervening pharmacist prompting the provider to adjust therapy. Additionally, rapid diagnostics even in combination with templated comments may not provide all the needed information for interpretation in a complex clinical situation, or for bacteria with complex and multifaceted AMR mechanisms. Thus, the improvements noted between treatment groups could also be due to the insight an infectious disease specialist provides, expediting the need for adjustments. While ASPs can bolster the results of rapid diagnostics, Kunz-Coyne et al. (5) demonstrated microbiologic interventions improve antibiotic stewardship program initiatives in return. This multicenter, retrospective cohort study assessed patients with Escherichia coli or Klebsiella pneumoniae bacteremia determined to be blaCTX-M or blaKPC gene-producing. Both groups of patients received ASP review and intervention; one group was supported with rapid molecular diagnostic tests and the other through standard-of-care culturing techniques and susceptibility testing. The rapid diagnostic group had a significant decrease in time to both optimal and effective antimicrobial therapy despite antibiotic stewardship review in both groups. Additionally, the rapid diagnostic group was associated with improved time to clearance of blood cultures. Thus, ASP review in the absence of mRDTs would not have been sufficient to predict multidrug resistant, gram-negative bacteremia in the majority of cases. These results highlight the important role of strong laboratory collaborations with ASPs, contributing diagnostic support that matches institutional patient populations and local AMR epidemiology. Implementation of ASPs without diagnostic tools or diagnostic tools without the ASPs will only ever fall short of optimizing management of patients with BSI. BSI, bloodstream infections; AMR, antimicrobial resistance; mRDT, molecular rapid diagnostic tests; CRE, carbapenem-resistant Enterobacterales; ASP, antimicrobial stewardship program. blaKPC, Klebsiella pneumoniae Carbapenemase; blaCTX-M, CTX-M. All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: R. Humphries, CLSI AST Subcommittee and IDSA Diagnostics Committee. R. Humphries, consulting for Biomerieux, Merck, Roche, Qpex, Torus, Specific Diagnostics, NGD, Qiagen, data safety monitoring board or advisory board for Pattern and QPex. R. Humphries, Accelerate Diagnostics, Specific Diagnostics, and NGD. R. Humphries, Clinical and Laboratory Standards Institute. R. Humphries, support to institution from bioMerieux (grant), Qiagen (contract), Momentum (grant), IHMA (grant), Pattern (contract). None declared. None declared.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Infective AgentsPhenotypeGenotypeMicrobial Sensitivity TestsAnti-Bacterial AgentsDrug Resistance, Bacterial

Substanzen

Anti-Infective AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Vanderbilt University Medical Center, Nashville, USA.
  • Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.

ORCID-Profile: Romney Humphries

Förderung

  • bioMerieux
  • Qiagen
  • Momentum
  • IHMA
  • Pattern

Zitieren

APA

Ing, A., & Humphries, R. (2023). The Genotype—Phenotype Conundrum for Antimicrobial Susceptibility Testing. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvac159

Vancouver

Ing A, Humphries R. The Genotype—Phenotype Conundrum for Antimicrobial Susceptibility Testing. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvac159

BibTeX
@article{Ing2023,
  author = {Ing, Austin and Humphries, Romney},
  title = {The Genotype—Phenotype Conundrum for Antimicrobial Susceptibility Testing},
  journal = {Clinical Chemistry},
  year = {2023},
  doi = {10.1093/clinchem/hvac159}
}
Kostenlos starten →